The DiaSmokeFree Working Group send a letter to the American Diabetes Association (ADA) expressing concern and seeking correction of a couple of statements in the ADA guidelines regarding the use…
Professor Li Volti talked about the Replica project results with a presentation titled "The impact of cigarette smoke and reduced risk products aerosol on endothelial function: the REPLICA project"
As requested by experts in the letter: "Our hope is that, in light of scientific evidence, the FCTC and the European Union conduct a careful, balanced, and transparent review of the available scientific evidence regarding non-combustible products, compared to conventional cigarettes, to provide indispensable information for making decisions in the interest of millions of smokers."
At 11.15 am, October 19, prof. Polosa will host remotely the panel Longer Term Outcomes of Cessation and Harm Reduction with a presentation on "Changes in Health Symptoms - Results and Analysis Methodologies".
On behalf of CoEHAR, the Center of Excellence for the acceleration of Harm Reduction, Dr. Lia Emma, researcher of the Replica project, will attend the conference to present the abstract "Cytotoxicity evaluation of vanillin in electronic cigarette liquids on human aortic artery endothelial cells”.
“𝑊𝑒 𝑛𝑒𝑒𝑑 𝑡𝑜 𝑐𝑜𝑙𝑙𝑎𝑏𝑜𝑟𝑎𝑡𝑒 𝑡𝑜𝑔𝑒𝑡ℎ𝑒𝑟 𝑠𝑜 𝑡ℎ𝑎𝑡 𝑒𝑣𝑒𝑟𝑦 𝑠𝑖𝑛𝑔𝑙𝑒 𝑎𝑟𝑡𝑖𝑐𝑙𝑒 𝑏𝑒𝑐𝑜𝑚𝑒𝑠 𝑎𝑛 𝑒𝑑𝑢𝑐𝑎𝑡𝑖𝑜𝑛𝑎𝑙 𝑡𝑜𝑜𝑙. 𝑊𝑒 𝑑𝑜𝑛'𝑡 𝑤𝑎𝑛𝑡 𝑡𝑜 𝑝𝑢𝑛𝑖𝑠ℎ 𝑎𝑢𝑡ℎ𝑜𝑟𝑠 𝑓𝑜𝑟 𝑡ℎ𝑒𝑖𝑟 𝑗𝑢𝑛𝑘 𝑝𝑎𝑝𝑒𝑟𝑠, 𝑤𝑒 𝑤𝑎𝑛𝑡 𝑡𝑜 𝑝𝑟𝑜𝑣𝑖𝑑𝑒 𝑡ℎ𝑒 𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛 𝑡𝑜 𝑖𝑚𝑝𝑟𝑜𝑣𝑒”
The findings presented by CoEHAR researchers can contribute the discussions of ENDS for cessation and support harm reduction strategies in the world.
“However, it is important to understand a fact when talking about smoking: even today, nicotine is believed to play a major role in the developing of atherosclerosis” explains prof. Polosa “Nicotine does not cause atherosclerosis. In a survey conducted by SERMO on 1000 Italian doctors, it was found that 62 percent of the sample still think that atherosclerosis is caused by nicotine. The fact that 33 percent of the sample is made up of cardiologists is significant".
According the authors, for every 100 people, 10 to 19 are likely to quit using an e-cigarette; 12 to 16 using varenicline; and 10 to 18 using cytisine. This is compared to the 6 in 100 people likely to quit when using no medicine/e-cigarette or placebo. People using two forms of nicotine replacement therapy at the same time, for example, a combination of nicotine patch and nicotine gum, seemed to have similar rates of quitting to people using e-cigarettes, varenicline and cytisine.
The conference will bring together leading experts in the field to discuss the latest research on dyslipidemias and their management. Topics to be covered include the latest guidelines from the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS), as well as innovative topics such as environmental risk factors, including smoking, and their role in the progression of atherosclerosis.